To: Jurgis Bekepuris who wrote (55284 ) 6/8/2015 1:22:05 AM From: Jurgis Bekepuris 1 RecommendationRecommended By Mattyice
Read Replies (2) | Respond to of 78627 My top (>2%) positions in no particular order: FRFHF, JPM, LMCA, STRZA, SFY bonds, BRKB, SFTBY, TESB.BE, FRMO, MKL, LBTYA/K, GDWN.L In: Out: Fixed income: ~10% Cash: ~18% Sectors (kinda): Insurance (including BRKB and FRFHF): 23%, Malone/media: 12%, Banks: 6%, Oil 11%, Tech 2%, Various owner-operators (not included in other categories) 16% New positions: CHK, AXP, KHTRF Positions increased: PRDGF, FMCKP, DNR, FRFHF, SFTBY Positions reduced: DRAGF Positions eliminated: TPRE, AGIIL, MHNC, SRLN Flip-flop: I have eliminated most of my fixed income positions (AGIIL, MHNC, SRLN) not counting SFY bonds. I think that holding cash might be preferable here compared to holding various bond, bank loan, pref positions. I sold TPRE after deciding that their (re)insurance results and 2/20% cost headwind are too adverse for holding this position. I sold some more DRAGF after they announced the official bid for the company and the stock ran up. I am still holding some. Put some of DRAGF money into my oil basket with CHK, DNR purchases. After reviewing my oil positions, I don't think they are very attractive, so I might not buy more at current prices. In particular, I don't think that CHK, DNR are the best places to put future money. :) Increased positions in PRDGF, FMCKP, FRFHF, SFTBY at flat to lower prices. Bought exploratory position in AXP. I don't think the price is very attractive yet, but the company still has a good franchise and brand, so I'd like to have my toes in waiting for possibly better prices. Bought a small position in KHTRF - Canadian biotech/pharma holding company at a price close to cash assets with shareholder oriented management.